Physician profile
Jane Eun Lee
NPI 1871156018
$2,630.77
in general payments reported to CMS, 2019-2025
32 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $571 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $357.76 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $345.32 | 2024-2025 | Evenity, Tepezza, Prolia |
| Sequel Med Tech, LLC | $161.74 | 2025 | Twiist |
| Mannkind Corporation | $151.59 | 2024-2025 | |
| Dexcom, INC. | $135.20 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $128.13 | 2024-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $116.72 | 2024-2025 | Korlym |
| Insulet Corporation | $109.96 | 2024-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $109.52 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $98.54 | 2024-2025 | Tymlos |
| Neurocrine Biosciences, INC. | $96.66 | 2024-2025 | |
| Ibsa Pharma INC. | $93.34 | 2024-2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $83.79 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $62.87 | 2025 | Yorvipath |
| Beta Bionics, INC. | $62.70 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $57.69 | 2025 | Vykat Xr |
| Boston Scientific Corporation | $55.34 | 2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $54.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.02 | 2025 | |
| Xeris Pharmaceuticals, INC. | $45.47 | 2025 | Gvoke Hypopen |
| Globus Medical, INC. | $36.01 | 2025 | Senza |
| Chiesi USA, INC. | $26.39 | 2025 | Mycapssa |
| Averitas Pharma INC. | $25.70 | 2025 | Qutenza |
| Kyowa Kirin, INC. | $25.20 | 2024 | Crysvita |
| Abbott Laboratories | $23.93 | 2025 | Freestyle Libre 3 |
| Tolmar, INC. | $19.17 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $18.76 | 2024 | Nucala |
| Ascensia Diabetes Care US INC. | $18.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2025 | Jardiance |
| Rhythm Pharmaceuticals, INC. | $16.13 | 2025 | Imcivree |
| Acella Pharmaceuticals, LLC | $14.32 | 2025 | NP Thyroid 60 |
| Medtronic, INC. | $13.84 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.